ni-0801
mAbexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 16, 2010 (NCT01244607)
Timeline
Indications
Mechanism of action
- C-X-C motif chemokine 10INHIBITOR
CXCL10 inhibitor
Bispecific antibody that targets mesothelin, a tumor associated antigen, while neutralizing the CD47 "don't eat me" signal.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109379 ↗
Also known as
- ni-0801
- ni-0801
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01430429 | Phase 2 | Sep 5, 2011 | NovImmune SA |
| NCT01244607 | Phase 1 | Nov 16, 2010 | NovImmune SA |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NovImmune SA | For profit | 2 | 2 | 2 | 2010 |
1 organizations
Page 1 / 1